716 results on '"Camanni F"'
Search Results
2. A mathematical model in the analysis of the response to growth hormone treatment in pediatric patients with diagnosis of growth hormone deficiency
3. Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: Data from the GH Registry
4. Diagnosis of adult growth hormone deficiency: Still a matter of debate
5. Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease
6. Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa
7. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly
8. Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1–24) independently of the duration of the disease
9. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans
10. Short Procedure of GHRH Plus Arginine Test in Clinical Practice
11. Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy
12. Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women
13. Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults
14. Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension
15. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients
16. Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man
17. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man
18. Effects of cholinergic blockade by pirenzepine on insulin and glucose response to oral and intravenous glucose and to arginine load in obesity
19. Galanin positively modulates prolactin secretion in normal women
20. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity
21. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man
22. Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans
23. Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity
24. Diagnosis of growth hormone deficiency
25. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration
26. Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma
27. Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children
28. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging
29. Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Deficiency States: Pathophysiological, Diagnostic and Therapeutic Implications
30. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans
31. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone
32. The Regulation of Growth Hormone Secretion
33. Retesting Young Adults with Childhood-Onset Growth Hormone (GH) Deficiency with GH-Releasing-Hormone-Plus-Arginine Test*
34. Reduction of the pituitary GH releasable pool in short children with GH neurosecretory dysfunction
35. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study
36. The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis
37. Low Hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man
38. Neuroendocrinology of the humangrowth hormone-insulin-like growth factor I axis during ageing
39. 'Cured' Prolactinoma Patients After Transsphenoidal Adenomectomy: Prediction of Recurrence
40. Aspects of neurotransmitter control of GH secretion: basic and clinical studies
41. Session 23. Reproductive endocrinology
42. This letter was forwarded to Drs. E.Ghigo, E. Bartolotta, E. Imperiale, J. Bellone, G. Cardinale, G. Aimaretti, M.R. Valetto, V. Cherubini, M. Maccario, D. Cocchi and F. Camanni whose reply follows
43. Effect of the somatostatin analog D-Trp8, D-Cys14 on glucose, insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics
44. Influence of glucagon on plasma levels of potassium in man
45. Inhibition of thyrotropin and prolactin secretion by dopamine in man
46. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia
47. Hyperprolactinemia: neuroendocrine and diagnostic aspects
48. Prolactin releasing effect of sulpiride isomers in rats and man
49. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone
50. The hypophosphatemia’and hyperkalemic effect of arginine in man
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.